5 O
WARNINGS O
AND O
PRECAUTIONS O
Review O
the O
Full O
Prescribing O
Information O
for O
dabrafenib O
prior O
to O
initiation O
of O
MEKINIST O
in O
combination O
with O
dabrafenib O
. O

The O
following O
serious O
adverse O
reactions O
of O
dabrafenib O
as O
a O
single O
agent O
, O
which O
may O
occur O
when O
MEKINIST O
is O
used O
in O
combination O
with O
dabrafenib O
, O
are O
not O
described O
in O
the O
Full O
Prescribing O
Information O
for O
MEKINIST O
: O
* O
Tumor B-NonOSE_AE
promotion I-NonOSE_AE
in O
patients O
with O
BRAF B-Not_AE_Candidate
wild I-Not_AE_Candidate
- I-Not_AE_Candidate
type I-Not_AE_Candidate
melanoma I-Not_AE_Candidate
* O
Hemolytic B-OSE_Labeled_AE
anemia I-OSE_Labeled_AE
in I-OSE_Labeled_AE
patients I-OSE_Labeled_AE
with I-OSE_Labeled_AE
glucose I-OSE_Labeled_AE
- I-OSE_Labeled_AE
6 I-OSE_Labeled_AE
- I-OSE_Labeled_AE
phosphate I-OSE_Labeled_AE
dehydrogenase I-OSE_Labeled_AE
deficiency I-OSE_Labeled_AE
* O
New O
primary O
malignancies O
, O
cutaneous O
and O
non-cutaneous O
, O
can O
occur O
when O
MEKINIST O
is O
used O
in O
combination O
with O
dabrafenib O
. O

Monitor O
patients O
for O
new O
malignancies O
prior O
to O
initiation O
of O
therapy O
while O
on O
therapy O
, O
and O
following O
discontinuation O
of O
the O
combination O
treatment O
. O

( O
5.1 O
, O
2.3 O
) O
* O
Hemorrhage O
: O
Major O
hemorrhagic O
events O
can O
occur O
in O
patients O
receiving O
MEKINIST O
in O
combination O
with O
dabrafenib O
. O

Monitor O
for O
signs O
and O
symptoms O
of O
bleeding O
( O
5.2 O
, O
2.3 O
) O
* O
Venous O
Thromboembolism O
: O
Deep O
vein O
thrombosis O
and O
pulmonary O
embolism O
can O
occur O
in O
patients O
receiving O
MEKINIST O
in O
combination O
with O
dabrafenib O
. O

( O
5.3 O
, O
2.3 O
) O
. O

* O
Cardiomyopathy O
: O
Assess O
LVEF O
before O
treatment O
, O
after O
one O
month O
of O
treatment O
, O
then O
every O
2 O
to O
3 O
months O
thereafter O
. O

( O
5.4 O
, O
2.3 O
) O
* O
Ocular O
Toxicities O
: O
Perform O
ophthalmologic O
evaluation O
for O
any O
visual O
disturbances O
. O

For O
Retinal O
Vein O
Occlusion O
( O
RVO O
) O
, O
permanently O
discontinue O
MEKINIST O
. O

( O
5.5 O
, O
2.3 O
) O
* O
Interstitial O
Lung O
Disease O
( O
ILD O
) O
: O
Withhold O
MEKINIST O
for O
new O
or O
progressive O
unexplained O
pulmonary O
symptoms O
. O

Permanently O
discontinue O
MEKINIST O
for O
treatment-related O
ILD O
or O
pneumonitis O
. O

( O
5.6 O
, O
2.3 O
) O
* O
Serious O
Febrile O
Reactions O
can O
occur O
when O
MEKINIST O
is O
used O
in O
combination O
with O
dabrafenib O
. O

( O
5.7 O
, O
2.3 O
) O
* O
Serious O
Skin O
Toxicity O
: O
Monitor O
for O
skin O
toxicities O
and O
for O
secondary O
infections O
. O

Discontinue O
for O
intolerable O
Grade O
2 O
, O
or O
Grade O
3 O
or O
4 O
rash O
not O
improving O
within O
3 O
weeks O
despite O
interruption O
of O
MEKINIST O
. O

( O
5.8 O
, O
2.3 O
) O
* O
Hyperglycemia O
: O
Monitor O
serum O
glucose O
levels O
in O
patients O
with O
pre-existing O
diabetes O
or O
hyperglycemia O
. O

( O
5.9 O
, O
2.3 O
) O
* O
Embryofetal O
Toxicity O
: O
Can O
cause O
fetal O
harm O
. O

Advise O
females O
of O
reproductive O
potential O
of O
potential O
risk O
to O
the O
fetus O
. O

( O
5.10 O
, O
8.1 O
, O
8.6 O
) O
EXCERPT O
: O
5.1 O
New O
Primary O
Malignancies O
New O
primary O
malignancies B-OSE_Labeled_AE
, I-OSE_Labeled_AE
cutaneous I-OSE_Labeled_AE
and O
non-cutaneous O
, O
can O
occur O
when O
MEKINIST O
is O
used O
in O
combination O
with O
dabrafenib O
and O
with O
dabrafenib O
as O
a O
single O
agent O
[ O
refer O
to O
Full O
Prescribing O
Information O
for O
dabrafenib O
] O
. O

Cutaneous O
Malignancies O
: O
In O
Trial O
2 O
, O
the O
incidence O
of O
basal B-OSE_Labeled_AE
cell I-OSE_Labeled_AE
carcinoma I-OSE_Labeled_AE
was O
increased O
in O
patients O
receiving O
MEKINIST O
in O
combination O
with O
dabrafenib O
, O
with O
an O
incidence O
of O
9 O
% O
( O
5/55 O
) O
in O
patients O
receiving O
MEKINIST O
in O
combination O
with O
dabrafenib O
compared O
with O
2 O
% O
( O
1/53 O
) O
in O
patients O
receiving O
dabrafenib O
as O
a O
single O
agent O
. O

The O
range O
of O
time O
to O
diagnosis O
of O
basal B-OSE_Labeled_AE
cell I-OSE_Labeled_AE
carcinoma I-OSE_Labeled_AE
was O
28 O
to O
249 O
days O
in O
patients O
receiving O
MEKINIST O
in O
combination O
with O
dabrafenib O
and O
was O
197 O
days O
for O
the O
patient O
receiving O
dabrafenib O
as O
a O
single O
agent O
. O

Cutaneous B-OSE_Labeled_AE
squamous I-OSE_Labeled_AE
cell I-OSE_Labeled_AE
carcinomas I-OSE_Labeled_AE
( O
SCC O
) O
, O
including O
keratoacanthoma B-OSE_Labeled_AE
, O
occurred O
in O
7 O
% O
of O
patients O
receiving O
MEKINIST O
in O
combination O
with O
dabrafenib O
and O
19 O
% O
of O
patients O
receiving O
dabrafenib O
as O
a O
single O
agent O
. O

The O
range O
of O
time O
to O
diagnosis O
of O
cuSCC B-OSE_Labeled_AE
was O
136 O
to O
197 O
days O
in O
the O
combination O
arm O
and O
was O
9 O
to O
197 O
days O
in O
the O
arm O
receiving O
dabrafenib O
as O
a O
single O
agent O
. O

New B-NonOSE_AE
primary I-NonOSE_AE
melanoma I-NonOSE_AE
occurred O
in O
2 O
% O
( O
1/53 O
) O
of O
patients O
receiving O
dabrafenib O
and O
in O
none O
of O
the O
55 O
patients O
receiving O
MEKINIST O
in O
combination O
with O
dabrafenib O
. O

Perform O
dermatologic O
evaluations O
prior O
to O
initiation O
of O
MEKINIST O
in O
combination O
with O
dabrafenib O
, O
every O
2 O
months O
while O
on O
therapy O
, O
and O
for O
up O
to O
6 O
months O
following O
discontinuation O
of O
the O
combination O
. O

No O
dose O
modifications O
of O
MEKINIST O
or O
dabrafenib O
are O
recommended O
in O
patients O
who O
develop O
new O
primary O
cutaneous B-NonOSE_AE
malignancies I-NonOSE_AE
. O

Non-Cutaneous O
Malignancies O
: O
Based O
on O
its O
mechanism O
of O
action O
, O
dabrafenib O
may O
promote O
growth O
and O
development O
of O
malignancies B-NonOSE_AE
with O
activation O
of O
RAS O
through O
mutation O
or O
other O
mechanisms O
[ O
refer O
to O
the O
Full O
Prescribing O
Information O
for O
dabrafenib O
] O
. O

In O
patients O
receiving O
MEKINIST O
in O
combination O
with O
dabrafenib O
, O
four O
cases O
of O
non B-OSE_Labeled_AE
- I-OSE_Labeled_AE
cutaneous I-OSE_Labeled_AE
malignancies I-OSE_Labeled_AE
were O
identified O
: O
KRAS B-OSE_Labeled_AE
mutation I-OSE_Labeled_AE
- I-OSE_Labeled_AE
positive I-OSE_Labeled_AE
pancreatic I-OSE_Labeled_AE
adenocarcinoma I-OSE_Labeled_AE
( O
n O
= O
1 O
) O
, O
recurrent B-OSE_Labeled_AE
NRAS I-OSE_Labeled_AE
mutation I-OSE_Labeled_AE
- I-OSE_Labeled_AE
positive I-OSE_Labeled_AE
colorectal I-OSE_Labeled_AE
carcinoma I-OSE_Labeled_AE
( O
n O
= O
1 O
) O
, O
head B-OSE_Labeled_AE
and I-OSE_Labeled_AE
neck I-OSE_Labeled_AE
carcinoma I-OSE_Labeled_AE
( O
n O
= O
1 O
) O
, O
and O
glioblastoma B-OSE_Labeled_AE
( O
n O
= O
1 O
) O
. O

Monitor O
patients O
receiving O
the O
combination O
closely O
for O
signs O
or O
symptoms O
of O
non B-NonOSE_AE
- I-NonOSE_AE
cutaneous I-NonOSE_AE
malignancies I-NonOSE_AE
. O

If O
used O
in O
combination O
with O
dabrafenib O
, O
no O
dose O
modification O
is O
required O
for O
MEKINIST O
in O
patients O
who O
develop O
non B-NonOSE_AE
- I-NonOSE_AE
cutaneous I-NonOSE_AE
malignancies I-NonOSE_AE
. O

Permanently O
discontinue O
dabrafenib O
in O
patients O
who O
develop O
RAS B-NonOSE_AE
mutation I-NonOSE_AE
- I-NonOSE_AE
positive I-NonOSE_AE
non I-NonOSE_AE
- I-NonOSE_AE
cutaneous I-NonOSE_AE
malignancies I-NonOSE_AE
. O

5.2 O
Hemorrhage O
Hemorrhages B-OSE_Labeled_AE
, O
including O
major B-OSE_Labeled_AE
hemorrhages I-OSE_Labeled_AE
defined O
as O
symptomatic O
bleeding B-OSE_Labeled_AE
in O
a O
critical O
area O
or O
organ O
, O
can O
occur O
when O
MEKINIST O
is O
used O
in O
combination O
with O
dabrafenib O
. O

In O
Trial O
2 O
, O
treatment O
with O
MEKINIST O
in O
combination O
with O
dabrafenib O
resulted O
in O
an O
increased O
incidence O
and O
severity O
of O
any O
hemorrhagic B-OSE_Labeled_AE
event I-OSE_Labeled_AE
: O
16 O
% O
( O
9/55 O
) O
of O
patients O
treated O
with O
MEKINIST O
in O
combination O
with O
dabrafenib O
compared O
with O
2 O
% O
( O
1/53 O
) O
of O
patients O
treated O
with O
dabrafenib O
as O
a O
single O
agent O
. O

The O
major O
hemorrhagic B-OSE_Labeled_AE
events I-OSE_Labeled_AE
of O
intracranial B-OSE_Labeled_AE
or O
gastric O
hemorrhage I-OSE_Labeled_AE
occurred O
in O
5 O
% O
( O
3/55 O
) O
of O
patients O
treated O
with O
MEKINIST O
in O
combination O
with O
dabrafenib O
compared O
with O
none O
of O
the O
53 O
patients O
treated O
with O
dabrafenib O
as O
a O
single O
agent O
. O

Intracranial B-OSE_Labeled_AE
hemorrhage I-OSE_Labeled_AE
was O
fatal O
in O
two O
( O
4 O
% O
) O
patients O
receiving O
the O
combination O
of O
MEKINIST O
and O
dabrafenib O
. O

Permanently O
discontinue O
MEKINIST O
, O
and O
also O
permanently O
discontinue O
dabrafenib O
if O
administered O
in O
combination O
, O
for O
all O
Grade O
4 O
hemorrhagic B-NonOSE_AE
events I-NonOSE_AE
and O
for O
any O
Grade O
3 O
hemorrhagic O
events O
that O
do O
not O
improve O
. O

Withhold O
MEKINIST O
for O
up O
to O
3 O
weeks O
for O
Grade O
3 O
hemorrhagic B-NonOSE_AE
events I-NonOSE_AE
; O
if O
improved O
resume O
at O
a O
lower O
dose O
level O
. O

Withhold O
dabrafenib O
for O
Grade O
3 O
hemorrhagic B-NonOSE_AE
events I-NonOSE_AE
; O
if O
improved O
resume O
at O
a O
lower O
dose O
level O
. O

5.3 O
Venous O
Thromboembolism O
Venous B-OSE_Labeled_AE
thromboembolism I-OSE_Labeled_AE
can O
occur O
when O
MEKINIST O
is O
used O
in O
combination O
with O
dabrafenib O
. O

In O
Trial O
2 O
, O
treatment O
with O
MEKINIST O
in O
combination O
with O
dabrafenib O
resulted O
in O
an O
increased O
incidence O
of O
deep B-OSE_Labeled_AE
venous I-OSE_Labeled_AE
thrombosis I-OSE_Labeled_AE
( I-OSE_Labeled_AE
DVT I-OSE_Labeled_AE
) O
and O
pulmonary B-OSE_Labeled_AE
embolism I-OSE_Labeled_AE
( I-OSE_Labeled_AE
PE I-OSE_Labeled_AE
) O
: O
7 O
% O
( O
4/55 O
) O
of O
patients O
treated O
with O
MEKINIST O
in O
combination O
with O
dabrafenib O
compared O
with O
none O
of O
the O
53 O
patients O
treated O
with O
dabrafenib O
as O
a O
single O
agent O
. O

Pulmonary B-OSE_Labeled_AE
embolism I-OSE_Labeled_AE
was O
fatal B-NonOSE_AE
in O
one O
( O
2 O
% O
) O
patient O
receiving O
the O
combination O
of O
MEKINIST O
and O
dabrafenib O
. O

Advise O
patients O
to O
immediately O
seek O
medical O
care O
if O
they O
develop O
symptoms O
of O
DVT B-NonOSE_AE
or O
PE B-NonOSE_AE
, O
such O
as O
shortness B-NonOSE_AE
of I-NonOSE_AE
breath I-NonOSE_AE
, O
chest B-NonOSE_AE
pain I-NonOSE_AE
, O
or O
arm B-NonOSE_AE
or O
leg O
swelling I-NonOSE_AE
. O

Permanently O
discontinue O
MEKINIST O
and O
dabrafenib O
for O
life O
threatening O
PE B-NonOSE_AE
. O

Withhold O
MEKINIST O
for O
uncomplicated O
DVT B-NonOSE_AE
and O
PE B-NonOSE_AE
for O
up O
to O
3 O
weeks O
; O
if O
improved O
, O
MEKINIST O
may O
be O
resumed O
at O
a O
lower O
dose O
level O
. O

Do O
not O
modify O
the O
dose O
of O
dabrafenib O
[ O
see O
Dosage O
and O
Administration O
( O
2.3 O
) O
] O
. O

5.4 O
Cardiomyopathy O
Cardiomyopathy B-OSE_Labeled_AE
can O
occur O
when O
MEKINIST O
is O
administered O
as O
a O
single O
agent O
or O
when O
used O
in O
combination O
with O
dabrafenib O
. O

In O
Trial O
1 O
, O
cardiomyopathy B-OSE_Labeled_AE
( O
defined O
as O
cardiac B-OSE_Labeled_AE
failure I-OSE_Labeled_AE
, O
left B-OSE_Labeled_AE
ventricular I-OSE_Labeled_AE
dysfunction I-OSE_Labeled_AE
, O
or O
decreased B-OSE_Labeled_AE
left I-OSE_Labeled_AE
ventricular I-OSE_Labeled_AE
ejection I-OSE_Labeled_AE
fraction I-OSE_Labeled_AE
[ O
LVEF O
] O
) O
occurred O
in O
7 O
% O
( O
14/211 O
) O
of O
patients O
treated O
with O
MEKINIST O
; O
no O
chemotherapy-treated O
patients O
in O
Trial O
1 O
developed O
cardiomyopathy B-NonOSE_AE
. O

In O
Trial O
2 O
, O
cardiomyopathy B-OSE_Labeled_AE
occurred O
in O
9 O
% O
( O
5/55 O
) O
of O
patients O
treated O
with O
MEKINIST O
in O
combination O
with O
dabrafenib O
and O
in O
none O
of O
patients O
treated O
with O
dabrafenib O
as O
a O
single O
agent O
. O

The O
median O
time O
to O
onset O
of O
cardiomyopathy B-OSE_Labeled_AE
in O
patients O
treated O
with O
MEKINIST O
was O
63 O
days O
( O
range O
: O
16 O
to O
156 O
days O
) O
for O
Trial O
1 O
and O
86 O
days O
( O
range O
: O
27 O
to O
253 O
days O
) O
for O
Trial O
2 O
. O

Cardiomyopathy B-OSE_Labeled_AE
was O
identified O
within O
the O
first O
month O
of O
treatment O
with O
MEKINIST O
in O
5 O
of O
14 O
patients O
in O
Trial O
1 O
and O
in O
2 O
of O
5 O
patients O
in O
Trial O
2 O
. O

Development O
of O
cardiomyopathy B-NonOSE_AE
resulted O
in O
dose O
reduction O
( O
7/211 O
) O
and/or O
discontinuation O
( O
4/211 O
) O
of O
study O
drug O
in O
Trial O
1 O
, O
and O
resulted O
in O
dose O
reduction O
( O
4/55 O
) O
and/or O
dose O
interruption O
( O
1/55 O
) O
in O
Trial O
2 O
. O

Cardiomyopathy B-NonOSE_AE
resolved O
in O
10 O
of O
14 O
( O
71 O
% O
) O
patients O
in O
Trial O
1 O
and O
in O
all O
5 O
patients O
in O
Trial O
2 O
. O

Across O
clinical O
trials O
of O
MEKINIST O
administered O
either O
as O
a O
single O
agent O
( O
N O
= O
329 O
) O
, O
or O
in O
combination O
with O
dabrafenib O
( O
N O
= O
202 O
) O
, O
11 O
% O
and O
8 O
% O
of O
patients O
, O
respectively O
, O
developed O
evidence O
of O
cardiomyopathy B-OSE_Labeled_AE
( O
decrease B-OSE_Labeled_AE
in I-OSE_Labeled_AE
LVEF I-OSE_Labeled_AE
below O
institutional O
lower O
limits O
of O
normal O
with O
an O
absolute O
decrease B-OSE_Labeled_AE
in I-OSE_Labeled_AE
LVEF I-OSE_Labeled_AE
> O
=10 O
% O
below O
baseline O
) O
. O

Five O
percent O
and O
2 O
% O
in O
single-agent O
and O
in O
combination O
trials O
, O
respectively O
, O
demonstrated O
a O
decrease B-OSE_Labeled_AE
in I-OSE_Labeled_AE
LVEF I-OSE_Labeled_AE
below O
institutional O
lower O
limits O
of O
normal O
with O
an O
absolute O
decrease B-OSE_Labeled_AE
in I-OSE_Labeled_AE
LVEF I-OSE_Labeled_AE
of O
> O
=20 O
% O
below O
baseline O
. O

Assess O
LVEF O
by O
echocardiogram O
or O
multigated O
acquisition O
( O
MUGA O
) O
scan O
before O
initiation O
of O
MEKINIST O
as O
a O
single O
agent O
and O
in O
combination O
with O
dabrafenib O
, O
one O
month O
after O
initiation O
, O
and O
then O
at O
2- O
to O
3-month O
intervals O
while O
on O
treatment O
. O

Withhold O
treatment O
with O
MEKINIST O
for O
up O
to O
4 O
weeks O
if O
absolute O
LVEF B-NonOSE_AE
value I-NonOSE_AE
decreases I-NonOSE_AE
by O
10 O
% O
from O
pretreatment O
values O
and O
is O
less O
than O
the O
lower O
limit O
of O
normal O
. O

For O
symptomatic O
cardiomyopathy B-NonOSE_AE
or O
persistent O
, O
asymptomatic O
LV B-NonOSE_AE
dysfunction I-NonOSE_AE
that O
does O
not O
resolve O
within O
4 O
weeks O
, O
permanently O
discontinue O
MEKINIST O
and O
withhold O
dabrafenib O
. O

Resume O
dabrafenib O
at O
the O
same O
dose O
upon O
recovery O
of O
cardiac O
function O
[ O
see O
Dosage O
and O
Administration O
( O
2.3 O
) O
] O
. O

5.5 O
Ocular O
Toxicities O
Retinal B-OSE_Labeled_AE
Vein I-OSE_Labeled_AE
Occlusion I-OSE_Labeled_AE
( O
RVO O
) O
: O
Across O
all O
clinical O
trials O
of O
MEKINIST O
, O
the O
incidence O
of O
RVO B-OSE_Labeled_AE
was O
0.2 O
% O
( O
4/1,749 O
) O
. O

RVO B-NonOSE_AE
may O
lead O
to O
macular B-NonOSE_AE
edema I-NonOSE_AE
, O
decreased B-NonOSE_AE
visual I-NonOSE_AE
function I-NonOSE_AE
, O
neovascularization B-NonOSE_AE
, O
and O
glaucoma B-NonOSE_AE
. O

Urgently O
( O
within O
24 O
hours O
) O
perform O
ophthalmological O
evaluation O
for O
patient-reported O
loss B-NonOSE_AE
of I-NonOSE_AE
vision I-NonOSE_AE
or O
other O
visual B-NonOSE_AE
disturbances I-NonOSE_AE
. O

Permanently O
discontinue O
MEKINIST O
in O
patients O
with O
documented O
RVO B-NonOSE_AE
. O

If O
MEKINIST O
is O
used O
in O
combination O
with O
dabrafenib O
, O
do O
not O
modify O
dabrafenib O
dose O
[ O
see O
Dosage O
and O
Administration O
( O
2.3 O
) O
] O
. O

Retinal O
Pigment O
Epithelial O
Detachment O
( O
RPED O
) O
: O
Retinal B-OSE_Labeled_AE
pigment I-OSE_Labeled_AE
epithelial I-OSE_Labeled_AE
detachment I-OSE_Labeled_AE
( I-OSE_Labeled_AE
RPED I-OSE_Labeled_AE
) O
can O
occur O
when O
MEKINIST O
is O
administered O
as O
a O
single O
agent O
or O
when O
used O
in O
combination O
with O
dabrafenib O
. O

In O
Trial O
1 O
and O
Trial O
2 O
, O
ophthalmologic O
examinations O
including O
retinal O
evaluation O
were O
performed O
pretreatment O
and O
at O
regular O
intervals O
during O
treatment O
. O

In O
Trial O
1 O
, O
one O
patient O
( O
0.5 O
% O
) O
receiving O
MEKINIST O
developed O
RPED B-OSE_Labeled_AE
and O
no O
cases O
of O
RPED O
were O
identified O
in O
chemotherapy-treated O
patients O
. O

Across O
all O
clinical O
trials O
of O
MEKINIST O
, O
the O
incidence O
of O
RPED B-OSE_Labeled_AE
was O
0.8 O
% O
( O
14/1,749 O
) O
. O

Retinal B-OSE_Labeled_AE
detachments I-OSE_Labeled_AE
were O
often O
bilateral O
and O
multifocal O
, O
occurring O
in O
the O
macular O
region O
of O
the O
retina O
. O

RPED B-OSE_Labeled_AE
led O
to O
reduction B-NonOSE_AE
in I-NonOSE_AE
visual I-NonOSE_AE
acuity I-NonOSE_AE
that O
resolved O
after O
a O
median O
of O
11.5 O
days O
( O
range O
: O
3 O
to O
71 O
days O
) O
following O
the O
interruption O
of O
dosing O
with O
MEKINIST O
, O
although O
Ocular B-NonOSE_AE
Coherence I-NonOSE_AE
Tomography I-NonOSE_AE
( I-NonOSE_AE
OCT I-NonOSE_AE
) I-NonOSE_AE
abnormalities I-NonOSE_AE
persisted O
beyond O
a O
month O
in O
at O
least O
several O
cases O
. O

In O
Trial O
2 O
, O
one O
patient O
( O
2 O
% O
) O
receiving O
MEKINIST O
in O
combination O
with O
dabrafenib O
developed O
RPED B-OSE_Labeled_AE
. O

Perform O
ophthalmological O
evaluation O
at O
any O
time O
a O
patient O
reports O
visual B-NonOSE_AE
disturbances I-NonOSE_AE
and O
compare O
with O
baseline O
, O
if O
available O
. O

Withhold O
MEKINIST O
if O
RPED O
is O
diagnosed O
. O

If O
resolution O
of O
the O
RPED B-NonOSE_AE
is O
documented O
on O
repeat O
ophthalmological O
evaluation O
within O
3 O
weeks O
, O
resume O
MEKINIST O
at O
a O
lower O
dose O
level O
. O

Discontinue O
MEKINIST O
if O
no O
improvement O
after O
3 O
weeks O
. O

If O
MEKINIST O
is O
used O
in O
combination O
with O
dabrafenib O
, O
do O
not O
modify O
the O
dose O
of O
dabrafenib O
[ O
see O
Dosage O
and O
Administration O
( O
2.3 O
) O
] O
. O

Uveitis O
and O
Iritis O
: O
Uveitis B-OSE_Labeled_AE
and O
iritis B-OSE_Labeled_AE
can O
occur O
when O
MEKINIST O
is O
used O
in O
combination O
with O
dabrafenib O
and O
with O
dabrafenib O
as O
a O
single O
agent O
[ O
refer O
to O
Full O
Prescribing O
Information O
for O
dabrafenib O
] O
. O

Uveitis B-OSE_Labeled_AE
occurred O
in O
1 O
% O
( O
2/202 O
) O
of O
patients O
treated O
with O
MEKINIST O
in O
combination O
with O
dabrafenib O
. O

Symptomatic O
treatment O
employed O
in O
clinical O
trials O
included O
steroid O
and O
mydriatic O
ophthalmic O
drops O
. O

Monitor O
patients O
for O
visual O
signs O
and O
symptoms O
of O
uveitis B-NonOSE_AE
( O
e.g. O
, O
change B-NonOSE_AE
in I-NonOSE_AE
vision I-NonOSE_AE
, O
photophobia B-NonOSE_AE
, O
eye B-NonOSE_AE
pain I-NonOSE_AE
) O
. O

If O
diagnosed O
, O
withhold O
dabrafenib O
for O
up O
to O
6 O
weeks O
until O
uveitis B-NonOSE_AE
/ O
iritis B-NonOSE_AE
resolves O
to O
Grade O
0-1 O
. O

If O
not O
improved O
, O
permanently O
discontinue O
dabrafenib O
. O

If O
MEKINIST O
is O
used O
in O
combination O
with O
dabrafenib O
, O
do O
not O
modify O
the O
dose O
of O
MEKINIST O
[ O
see O
Dosage O
and O
Administration O
( O
2.3 O
) O
] O
. O

5.6 O
Interstitial O
Lung O
Disease O
In O
clinical O
trials O
of O
MEKINIST O
( O
N O
= O
329 O
) O
as O
a O
single O
agent O
, O
ILD B-OSE_Labeled_AE
or O
pneumonitis B-OSE_Labeled_AE
occurred O
in O
2 O
% O
of O
patients O
. O

In O
Trial O
1 O
, O
2 O
% O
( O
5/211 O
) O
of O
patients O
treated O
with O
MEKINIST O
developed O
ILD B-OSE_Labeled_AE
or O
pneumonitis B-OSE_Labeled_AE
; O
all O
five O
patients O
required O
hospitalization O
. O

The O
median O
time O
to O
first O
presentation O
of O
ILD B-OSE_Labeled_AE
or O
pneumonitis B-OSE_Labeled_AE
was O
160 O
days O
( O
range O
: O
60 O
to O
172 O
days O
) O
. O

Withhold O
MEKINIST O
in O
patients O
presenting O
with O
new O
or O
progressive O
pulmonary O
symptoms O
and O
findings O
including O
cough B-NonOSE_AE
, O
dyspnea B-NonOSE_AE
, O
hypoxia B-NonOSE_AE
, O
pleural B-NonOSE_AE
effusion I-NonOSE_AE
, O
or O
infiltrates B-NonOSE_AE
, O
pending O
clinical O
investigations O
. O

Permanently O
discontinue O
MEKINIST O
for O
patients O
diagnosed O
with O
treatment-related O
ILD B-NonOSE_AE
or O
pneumonitis B-NonOSE_AE
. O

If O
MEKINIST O
is O
used O
in O
combination O
with O
dabrafenib O
, O
do O
not O
modify O
the O
dose O
of O
dabrafenib O
[ O
see O
Dosage O
and O
Administration O
( O
2.3 O
) O
] O
. O

5.7 O
Serious O
Febrile O
Reactions O
Serious O
febrile B-OSE_Labeled_AE
reactions I-OSE_Labeled_AE
and O
fever B-OSE_Labeled_AE
of O
any O
severity O
accompanied O
by O
hypotension B-OSE_Labeled_AE
, O
rigors B-OSE_Labeled_AE
or O
chills B-OSE_Labeled_AE
, O
dehydration B-OSE_Labeled_AE
, O
or O
renal B-OSE_Labeled_AE
failure I-OSE_Labeled_AE
, O
can O
occur O
when O
MEKINIST O
is O
used O
in O
combination O
with O
dabrafenib O
and O
with O
dabrafenib O
as O
a O
single O
agent O
[ O
refer O
to O
Full O
Prescribing O
Information O
for O
dabrafenib O
] O
. O

The O
incidence O
and O
severity O
of O
pyrexia B-OSE_Labeled_AE
are O
increased O
when O
MEKINIST O
is O
used O
in O
combination O
with O
dabrafenib O
compared O
with O
dabrafenib O
as O
a O
single O
agent O
[ O
see O
Adverse O
Reactions O
( O
6.1 O
) O
] O
. O

In O
Trial O
2 O
, O
the O
incidence O
of O
fever B-OSE_Labeled_AE
( O
serious O
and O
non-serious O
) O
was O
71 O
% O
( O
39/55 O
) O
in O
patients O
treated O
with O
MEKINIST O
in O
combination O
with O
dabrafenib O
and O
26 O
% O
( O
14/53 O
) O
in O
patients O
treated O
with O
dabrafenib O
as O
a O
single O
agent O
. O

Serious O
febrile B-OSE_Labeled_AE
reactions I-OSE_Labeled_AE
and O
fever B-OSE_Labeled_AE
of O
any O
severity O
accompanied O
by O
hypotension B-OSE_Labeled_AE
, O
rigors B-OSE_Labeled_AE
, O
or O
chills B-OSE_Labeled_AE
occurred O
in O
25 O
% O
( O
14/55 O
) O
of O
patients O
treated O
with O
MEKINIST O
in O
combination O
with O
dabrafenib O
compared O
with O
2 O
% O
( O
1/53 O
) O
of O
patients O
treated O
with O
dabrafenib O
as O
a O
single O
agent O
. O

Fever B-OSE_Labeled_AE
was O
complicated O
with O
chills B-OSE_Labeled_AE
/ O
rigors B-OSE_Labeled_AE
in O
51 O
% O
( O
28/55 O
) O
, O
dehydration B-OSE_Labeled_AE
in O
9 O
% O
( O
5/55 O
) O
, O
renal B-OSE_Labeled_AE
failure I-OSE_Labeled_AE
in O
4 O
% O
( O
2/55 O
) O
, O
and O
syncope B-OSE_Labeled_AE
in O
4 O
% O
( O
2/55 O
) O
of O
patients O
in O
Trial O
2 O
. O

In O
patients O
treated O
with O
MEKINIST O
in O
combination O
with O
dabrafenib O
, O
the O
median O
time O
to O
initial O
onset O
of O
fever B-OSE_Labeled_AE
was O
30 O
days O
compared O
with O
19 O
days O
in O
patients O
treated O
with O
dabrafenib O
as O
a O
single O
agent O
; O
the O
median O
duration O
of O
fever B-OSE_Labeled_AE
was O
6 O
days O
with O
the O
combination O
compared O
with O
4 O
days O
with O
dabrafenib O
as O
a O
single O
agent O
. O

Across O
clinical O
trials O
of O
MEKINIST O
administered O
in O
combination O
with O
dabrafenib O
( O
N O
= O
202 O
) O
, O
the O
incidence O
of O
pyrexia B-OSE_Labeled_AE
was O
57 O
% O
( O
116/202 O
) O
. O

Withhold O
dabrafenib O
for O
fever B-NonOSE_AE
of O
101.3oF O
or O
higher O
. O

Withhold O
MEKINIST O
for O
fever B-NonOSE_AE
higher O
than O
104oF O
. O

Withhold O
dabrafenib O
and O
MEKINIST O
for O
any O
serious O
febrile B-NonOSE_AE
reaction I-NonOSE_AE
or O
fever B-NonOSE_AE
accompanied O
by O
hypotension B-NonOSE_AE
, O
rigors B-NonOSE_AE
or O
chills B-NonOSE_AE
, O
dehydration B-NonOSE_AE
, O
or O
renal B-NonOSE_AE
failure I-NonOSE_AE
, O
and O
evaluate O
for O
signs O
and O
symptoms O
of O
infection B-NonOSE_AE
. O

Refer O
to O
Table O
2 O
for O
recommended O
dose O
modifications O
for O
adverse O
reactions O
[ O
see O
Dosage O
and O
Administration O
( O
2.3 O
) O
] O
. O

Prophylaxis O
with O
antipyretics O
may O
be O
required O
when O
resuming O
MEKINIST O
or O
dabrafenib O
. O

5.8 O
Serious O
Skin O
Toxicity O
Serious O
skin B-OSE_Labeled_AE
toxicity I-OSE_Labeled_AE
can O
occur O
when O
MEKINIST O
is O
administered O
as O
a O
single O
agent O
or O
when O
used O
in O
combination O
with O
dabrafenib O
. O

Serious O
skin B-NonOSE_AE
toxicity I-NonOSE_AE
can O
also O
occur O
with O
dabrafenib O
as O
a O
single O
agent O
[ O
refer O
to O
Full O
Prescribing O
Information O
for O
dabrafenib O
] O
. O

In O
Trial O
1 O
, O
the O
overall O
incidence O
of O
any O
skin B-OSE_Labeled_AE
toxicity I-OSE_Labeled_AE
, O
the O
most O
common O
of O
which O
were O
rash B-OSE_Labeled_AE
, O
dermatitis B-OSE_Labeled_AE
acneiform I-OSE_Labeled_AE
rash I-OSE_Labeled_AE
, O
palmar B-OSE_Labeled_AE
- I-OSE_Labeled_AE
plantar I-OSE_Labeled_AE
erythrodysesthesia I-OSE_Labeled_AE
syndrome I-OSE_Labeled_AE
, O
and O
erythema B-OSE_Labeled_AE
, O
was O
87 O
% O
in O
patients O
treated O
with O
MEKINIST O
and O
13 O
% O
in O
chemotherapy-treated O
patients O
. O

Severe O
skin B-OSE_Labeled_AE
toxicity I-OSE_Labeled_AE
occurred O
in O
12 O
% O
of O
patients O
treated O
with O
MEKINIST O
. O

Skin B-OSE_Labeled_AE
toxicity I-OSE_Labeled_AE
requiring O
hospitalization O
occurred O
in O
6 O
% O
of O
patients O
treated O
with O
MEKINIST O
, O
most O
commonly O
for O
secondary O
infections B-NonOSE_AE
of I-NonOSE_AE
the I-NonOSE_AE
skin I-NonOSE_AE
requiring O
intravenous O
antibiotics O
or O
severe O
skin B-OSE_Labeled_AE
toxicity I-OSE_Labeled_AE
without O
secondary B-NonOSE_AE
infection I-NonOSE_AE
. O

In O
comparison O
, O
no O
patients O
treated O
with O
chemotherapy O
required O
hospitalization O
for O
severe O
skin B-NonOSE_AE
toxicity I-NonOSE_AE
or O
infections B-NonOSE_AE
of I-NonOSE_AE
the I-NonOSE_AE
skin I-NonOSE_AE
. O

The O
median O
time O
to O
onset O
of O
skin B-OSE_Labeled_AE
toxicity I-OSE_Labeled_AE
in O
patients O
treated O
with O
MEKINIST O
was O
15 O
days O
( O
range O
: O
1 O
to O
221 O
days O
) O
and O
median O
time O
to O
resolution O
of O
skin B-OSE_Labeled_AE
toxicity I-OSE_Labeled_AE
was O
48 O
days O
( O
range O
: O
1 O
to O
282 O
days O
) O
. O

Reductions O
in O
the O
dose O
of O
MEKINIST O
were O
required O
in O
12 O
% O
and O
permanent O
discontinuation O
of O
MEKINIST O
was O
required O
in O
1 O
% O
of O
patients O
with O
skin B-OSE_Labeled_AE
toxicity I-OSE_Labeled_AE
. O

In O
Trial O
2 O
, O
the O
incidence O
of O
any O
skin B-OSE_Labeled_AE
toxicity I-OSE_Labeled_AE
was O
similar O
for O
patients O
receiving O
MEKINIST O
in O
combination O
with O
dabrafenib O
( O
65 O
% O
[ O
36/55 O
] O
) O
compared O
with O
patients O
receiving O
dabrafenib O
as O
a O
single O
agent O
( O
68 O
% O
[ O
36/53 O
] O
) O
. O

The O
median O
time O
to O
onset O
of O
skin B-OSE_Labeled_AE
toxicity I-OSE_Labeled_AE
in O
patients O
treated O
with O
MEKINIST O
in O
combination O
with O
dabrafenib O
was O
37 O
days O
( O
range O
: O
1 O
to O
225 O
days O
) O
and O
median O
time O
to O
resolution O
of O
skin B-OSE_Labeled_AE
toxicity I-OSE_Labeled_AE
was O
33 O
days O
( O
range O
: O
3 O
to O
421 O
days O
) O
. O

No O
patient O
required O
dose O
reduction O
or O
permanent O
discontinuation O
of O
MEKINIST O
or O
dabrafenib O
for O
skin B-NonOSE_AE
toxicity I-NonOSE_AE
. O

Across O
clinical O
trials O
of O
MEKINIST O
administered O
in O
combination O
with O
dabrafenib O
( O
n O
= O
202 O
) O
, O
severe O
skin B-OSE_Labeled_AE
toxicity I-OSE_Labeled_AE
and O
secondary O
infection B-NonOSE_AE
of I-NonOSE_AE
the I-NonOSE_AE
skin I-NonOSE_AE
requiring O
hospitalization O
occurred O
in O
2.5 O
% O
( O
5/202 O
) O
of O
patients O
treated O
with O
MEKINIST O
in O
combination O
with O
dabrafenib O
. O

Withhold O
MEKINIST O
, O
and O
dabrafenib O
if O
used O
in O
combination O
, O
for O
intolerable O
or O
severe O
skin B-NonOSE_AE
toxicity I-NonOSE_AE
. O

MEKINIST O
and O
dabrafenib O
may O
be O
resumed O
at O
lower O
dose O
levels O
in O
patients O
with O
improvement O
or O
recovery O
from O
skin B-NonOSE_AE
toxicity I-NonOSE_AE
within O
3 O
weeks O
[ O
see O
Dosage O
and O
Administration O
( O
2.3 O
) O
] O
. O

5.9 O
Hyperglycemia O
Hyperglycemia B-OSE_Labeled_AE
can O
occur O
when O
MEKINIST O
is O
used O
in O
combination O
with O
dabrafenib O
and O
with O
dabrafenib O
as O
a O
single O
agent O
. O

Hyperglycemia B-NonOSE_AE
requiring O
an O
increase O
in O
the O
dose O
of O
, O
or O
initiation O
of O
insulin O
or O
oral O
hypoglycemic O
agent O
therapy O
occurred O
with O
dabrafenib O
as O
a O
single O
agent O
[ O
refer O
to O
Full O
Prescribing O
Information O
for O
dabrafenib O
] O
. O

In O
Trial O
2 O
, O
the O
incidence O
of O
Grade O
3 O
hyperglycemia B-OSE_Labeled_AE
based O
on O
laboratory O
values O
was O
5 O
% O
( O
3/55 O
) O
in O
patients O
treated O
with O
MEKINIST O
in O
combination O
with O
dabrafenib O
compared O
with O
2 O
% O
( O
1/53 O
) O
in O
patients O
treated O
with O
dabrafenib O
as O
a O
single O
agent O
. O

Monitor O
serum O
glucose O
levels O
as O
clinically O
appropriate O
during O
treatment O
with O
MEKINIST O
in O
combination O
with O
dabrafenib O
in O
patients O
with O
pre-existing O
diabetes B-Not_AE_Candidate
or O
hyperglycemia B-Not_AE_Candidate
. O

Advise O
patients O
to O
report O
symptoms O
of O
severe O
hyperglycemia B-NonOSE_AE
. O

5.10 O
Embryofetal B-OSE_Labeled_AE
Toxicity I-OSE_Labeled_AE
Based O
on O
its O
mechanism O
of O
action O
, O
MEKINIST O
can O
cause O
fetal B-OSE_Labeled_AE
harm I-OSE_Labeled_AE
when O
administered O
to O
a O
pregnant B-Not_AE_Candidate
woman O
. O

MEKINIST O
was O
embryotoxic B-NonOSE_AE
and O
abortifacient B-NonOSE_AE
in O
rabbits O
at O
doses O
greater O
than O
or O
equal O
to O
those O
resulting O
in O
exposures O
approximately O
0.3 O
times O
the O
human O
exposure O
at O
the O
recommended O
clinical O
dose O
. O

If O
this O
drug O
is O
used O
during O
pregnancy B-Not_AE_Candidate
, O
or O
if O
the O
patient O
becomes O
pregnant B-NonOSE_AE
while O
taking O
this O
drug O
, O
the O
patient O
should O
be O
apprised O
of O
the O
potential O
hazard B-OSE_Labeled_AE
to I-OSE_Labeled_AE
a I-OSE_Labeled_AE
fetus I-OSE_Labeled_AE
[ O
see O
Use O
in O
Specific O
Populations O
( O
8.1 O
) O
] O
. O

Advise O
female O
patients O
of O
reproductive O
potential O
to O
use O
highly O
effective O
contraception O
during O
treatment O
with O
MEKINIST O
and O
for O
4 O
months O
after O
treatment O
. O

Advise O
patients O
to O
use O
a O
highly O
effective O
non-hormonal O
method O
of O
contraception O
when O
MEKINIST O
is O
administered O
in O
combination O
with O
dabrafenib O
, O
since O
dabrafenib O
can O
render O
hormonal O
contraceptives O
ineffective O
. O

Advise O
patients O
to O
contact O
their O
healthcare O
provider O
if O
they O
become O
pregnant B-NonOSE_AE
, O
or O
if O
pregnancy B-Not_AE_Candidate
is O
suspected O
, O
while O
taking O
MEKINIST O
[ O
see O
Use O
in O
Specific O
Populations O
( O
8.1 O
, O
8.6 O
) O
] O
. O

